SAN DIEGO & TOKYO, June 04, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the . This company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +13.6%. Sat, 04 Jun 2022 MEI Pharma (MEIP) Stock Price: Why It Increased . Alliance Global Partners Thinks MEI Pharma's Stock is Going to Recover. msn back to msn home money. Find real-time MEIP - MEI Pharma Inc stock quotes, company profile, news and forecasts from CNN Business. The average price target is $5.00 with a high forecast of $15.00 and a low forecast of $1.00. Complete MEI Pharma Inc. stock information by Barron's. View real-time MEIP stock price and news, along with industry-best analysis. Today's 52-Week Highs; Today's 52-Week Lows; Volume . What was the 52-week high for MEI Pharma stock? As of 2022 June 05, Sunday current price of MEIP stock is 0.527$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. MEI Pharma stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. This suggests a possible upside of 710.9% from the stock's current price. Get the latest MEI Pharma, Inc MEIP detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. On average, analysts forecast that MEIP's EPS will be -$0.59 for 2022, with the . The average MEI PHARMA stock price prediction forecasts a potential upside of 518.56% from the current MEIP share price of $0.46. See MEI Pharma, Inc. (MEIP) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The. Its drug candidates include Pracinostat, an oral HDAC inhibitor . Alliance Global Partners analyst Matthew Cross maintained a Buy rating on MEI Pharma (MEIP - Research Report) today and set a price target of $9.00. MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. web search. . MarketBeat recorded 5 mentions for MEI Pharma and 4 mentions for AC Immune. The low in the last 52 weeks of MEI Pharma stock was 0.41. According to the current price, MEI Pharma is 132.93% away from the 52-week low. MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. (NASDAQ: MEIP) MEI PHARMA's current Earnings Per Share (EPS) is -$0.41. MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. According to the issued ratings of 7 analysts in the last year, the consensus rating for MEI Pharma stock is Buy based on the current 3 hold ratings and 4 buy ratings for MEIP. . The average twelve-month price prediction for MEI Pharma is $5.13 with a high price target of $20.00 and a low price target of $1.00. MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the expansion of its management team with the addition of two . Estimates. The average MEI PHARMA stock price prediction forecasts a potential upside of 437.57% from the current MEIP share price of $0.53. Investors in MEI Pharma, Inc. (MEIP Quick Quote MEIP - Free Report) need to pay close attention to the stock based on moves in the options market lately.That is because the Jun 19, 2020 $5.00 Call . In depth view into MEI Pharma Issuance of Stock explanation, calculation, historical data and more MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an . The 6 analysts offering price forecasts for MEI Pharma have a median target of 3.00, with a high estimate of 5.00 and a low estimate of 1.00. About MEI Pharma. The average price target is $5.00 with a high forecast of $15.00 and a low forecast of $1.00. The latest price target for . On average, Wall Street analysts predict that MEI PHARMA 's share price could reach $2.83 by Mar 25, 2023. Q3 2021. Find real-time MEIP - MEI Pharma Inc stock quotes, company profile, news and forecasts from CNN Business. In-depth view of key statistics and finances for MEI PHARMA, INC. (MEIP) on MSN Money. MEI Pharma Inc. MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Their forecasts range from $1.00 to $20.00. A. View MEI Pharma, Inc MEIP investment & stock information. MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -46.67% and 340.09%, respectively, for the quarter ended December 2020. Quarterly Numbers. Sector Health Care Industry Biotechnology Employees 76 Founded 2000 Address 11455 El Camino Real San. MEIP : 0.5566 (-6.03%) MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments Business Wire - Mon Feb 7, 7:00AM CST. Complete MEI Pharma Inc. stock information by Barron's. View real-time MEIP stock price and news, along with industry-best analysis. MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. . This means that if you invested $100 now, your current investment may be worth 0$ on 2023 June 05, Monday. Actuals. msn back to msn home money. . More. MEIP will report Q3 2022 earnings on 09/01/2022. The company's shares closed last Thursday at $1.83, close to its 52-week low of $1.68. What are analysts forecasts for MEI Pharma stock? MEI Pharma (NASDAQ: MEIP) was reported by BTIG on March 25, 2022.The analyst firm set a price target for $4.00 expecting MEIP to rise to within 12 months (a possible . Get the latest MEI Pharma, Inc MEIP detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. MEI Pharma expands early-stage zandelisib trial in specific blood cancer cohorts SA News Mon, Jan. 04, 2021 1 Comment MEI Pharma EPS misses by $0.06, beats on revenue MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates. On average, they expect MEI Pharma's share price to reach $5.13 in the next year. On average, they expect MEI Pharma's share price to reach $5.13 in the next year. San Diego - December 1, 2021 - MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has priced the underwritten public offering of 17,500,000 shares of its common stock at $2.60 per share for total gross proceeds (before underwriting discount and commissions . MEIP Stock Predictions, Articles, and Mei Pharma Inc News From InvestorPlace From the Web 27 Biotechnology Stocks to Sell Now By Portfolio Grader Nov 7, 2016 This week, 27 Biotechnology stocks are . While ratings are subjective and will change, the latest MEI Pharma ( MEIP) rating was a maintained with a price target of $11.00 to $4.00. Revenues are expected to be $7.62 million, down 16.9%. What is MEIP's Earnings Per Share (EPS) forecast for 2022-2024? Shares in MEI Pharma ( MEIP -3.51%) are tumbling 15.3% at 11:55 a.m. EDT on Thursday following news its collaboration partner, Helsinn Group, is discontinuing a phase 3 trial of pracinostat in. These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks. MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. The highest, average, and lowest price target of all analysts. See MEI Pharma, Inc. (MEIP) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. About MEI Pharma. The average price target represents a 787.78% change from the last price of $0.56. View analysts' price targets for MEI Pharma or view top-rated stocks among Wall Street analysts. MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates. Q4 2021. The Opinions takes up to 5 years' worth of historical data and runs these prices through thirteen different technical indicators. A high-level overview of MEI Pharma, Inc. (MEIP) stock. web search. Today's 52-Week Highs; Today's 52-Week Lows; Volume . In-depth view of key statistics and finances for MEI PHARMA, INC. (MEIP) on MSN Money. The average price target represents a 787.78% change from the last price of $0.56. A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol. MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm BU 05/17 What is MEIP's Earnings Per Share (EPS) forecast for 2022-2024? The average twelve-month price prediction for MEI Pharma is $5.13 with a high price target of $20.00 and a low price target of $1.00. In the previous week, MEI Pharma had 1 more articles in the media than AC Immune. MEIP : 0.5566 (-6.03%) MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments Business Wire - Mon Feb 7, 7:00AM CST. Their forecasts range from $1.00 to $20.00. 6 Wall Street analysts have issued 12-month price targets for MEI Pharma's shares. Stock Picks. MEIP updated stock price target summary. This suggests a possible upside of 710.9% from the stock's current price. MEIP Issuance of Stock as of today (June 05, 2022) is $52.26 Mil. MEI Pharma's portfolio of drug candidates . MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food . Barchart Opinions show traders what a variety of popular trading systems are suggesting in terms of going long or short the market. According to the issued ratings of 7 analysts in the last year, the consensus rating for MEI Pharma stock is Buy based on the current 3 hold ratings and 4 buy ratings for MEIP. Stock Picks. AC Immune's average media sentiment score of 0.84 beat MEI Pharma's score of -0.42 indicating that AC Immune is being referred to more favorably in the media. About the MEI Pharma Inc stock forecast. Do the numbers hold clues to what lies ahead for the stock? Stock Price Prediction: Update at 5:00pm EST: If tomorrow: Open lower Open higher High: 0.56 - 0.57 0.57 - 0.57 Low: . 52-Week Range $0.41 - $3.55 Dividend & Yield N/A (N/A) MEIP Stock Predictions, Articles, and Mei Pharma Inc News From InvestorPlace From the Web 27 Biotechnology Stocks to Sell Now By Portfolio. Learn more on MEIP's analyst rating . Based on 9 Wall Street analysts offering 12 month price targets for MEI Pharma in the last 3 months. Real time MEI Pharma (MEIP) stock price quote, stock graph, news & analysis. The current price MEI Pharma ( MEIP) is trading at is . Based on 9 Wall Street analysts offering 12 month price targets for MEI Pharma in the last 3 months. MEI Pharma Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Interactive Chart MEIP S&P 500 Index Compare MEIP Stock to Peers News & Analysis: MEI Pharma. (Expected Surprise Prediction) looks to find companies that have recently seen . MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the expansion of its management team with the addition of two . Future price of the stock is predicted at 0$ ( -100% ) after a year according to our prediction system. Past 12 Months 12 Months Forecast -$1 $3.25 $7.5 $11.75 $16 Aug 2021 Nov After each calculation, the program assigns a buy, sell or hold value for each study .